7 July 2011 -- Oncology treatment company Sirtex Medical (ASX: SRX) today announced the publication of a six-year retrospective analysis of 325 patients treated with its targeted radioactive SIR-Spheres® microspheres therapy for inoperable primary liver cancer.
The study is the largest multi-centre evaluation of radioembolisation (also known as Selective Internal Radiation Therapy or SIRT) using SIR-Spheres® microspheres for patients with inoperable primary liver cancer and the results confirm that the treatment was safe and effective in a range of patients with early to advanced stages of the disease.
Independent researchers at eight European treatment centres reported “robust evidence of the survival achieved” using SIR-Spheres® microspheres, “including patients with advanced disease and few treatment options.”
Sirtex Chief Executive Officer, Mr Gilman Wong, said, “These positive results build on the growing body of robust clinical evidence that demonstrates SIR-Spheres® microspheres deliver very encouraging clinical outcomes across the different stages of liver cancer.”
“This new data will further support the expanding use of SIR-Spheres® microspheres in a wider patient population and bolster our efforts to support medical professionals treating liver cancer patients at over 400 treatment centres worldwide,” Mr Wong said.
The full results of the multi-centre retrospective analysis called ENRY (European Network on Radioembolisation with Yttrium-90 Resin Microspheres) are published in the peer-reviewed journal of the American Association of the Study of Liver Diseases, Hepatology.
A summary of the key findings is attached and a full reprint is available online at
http://onlinelibrary.wiley.com/doi/10.1002/hep.24451/full or by contacting Sirtex.
City Public Relations
Level 6, 155 George Street
The Rocks Sydney NSW 2000
Direct: (02) 8916 4845
Switch: (02) 8916 4848
Mobile: 0408 677 734